Sana Biotechnology (SANA) Cash & Equivalents (2020 - 2026)

Sana Biotechnology (SANA) has 7 years of Cash & Equivalents data on file, last reported at $83.8 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 12.83% year-over-year to $83.8 million; the trailing twelve-month figure through Mar 2026 stood at $83.8 million (down 12.83% YoY), and the FY2025 full-year result was $71.9 million, down 43.66% from the prior year.
• Cash & Equivalents climbed to $83.8 million in Q1 2026, from $71.9 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $194.7 million in Q2 2022 to a low of $71.3 million in Q2 2025.
• A 5-year average of $138.4 million and a median of $135.0 million in 2024 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents slumped 74.89% in 2022 and gained 10.34% in 2024, its largest moves.
• Tracing SANA's Cash & Equivalents over 5 years: stood at $176.8 million in 2022, then slipped by 24.47% to $133.5 million in 2023, then dropped by 4.46% to $127.6 million in 2024, then plunged by 43.66% to $71.9 million in 2025, then increased by 16.6% to $83.8 million in 2026.
• Business Quant data shows SANA's Cash & Equivalents at $83.8 million in Q1 2026, $71.9 million in Q4 2025, and $103.4 million in Q3 2025.